EU Joint Programme- Antimicrobial Resistance JPIAMR 6th Transnational Call on “Innovation against antibiotic-resistant bacteria: new targets, compounds and tools; Fundamental, translational research, with the exception of clinical trials.”

The EU Joint Programming initiative on Antimicrobial-Resistance aims to improve controls, preventive measures, stewardship and intervention strategies to reduce the risk of antibiotic-resistant bacteria to people, animals and the environment. This call invites multinational consortia to develop new targets, compounds and tools for treatments (including new antibiotics). It covers fundamental and translational research, with the exception of clinical trials.


Scheme at a glance

EU co-funded
  • All
Career stage
  • Mid career
  • Senior career
Research area
  • Basic research
  • Health services research
  • Patient-oriented and clinical research
  • Population health research
Funding available The maximum funding for successful partner(s) from Ireland in this call is €370,000. It is anticipated 1 proposal will be funded.
Duration of funding Up to 36 months

Additional Information

In September 2017, WHO published the Global priority list of antibiotic-resistant bacteria across three priority classifications; critical, high and medium .  This call covers research on the bacterial pathogens and resistances identified by this report. Further details may be found in the JPIAMR call documents JPIAMR call documents.

The aim of the call is to address the identification and validation of new targets, the development of new therapies, and new tools for new treatments (including new antibiotics) through multidisciplinary studies. Proposals submitted under the call may include, but are not limited to, the following types of research:
•    New Targets: new bacterial targets or mechanisms of resistance including studies aimed at understanding and overcoming the mechanisms controlling the generation of resistance.

•    New therapies: discovery of new compounds (including antibiotics and alternatives). Strategies to inhibit or reduce the acquisition of resistance. Discovery of novel therapies to overcome known antimicrobial resistance mechanisms and/or restore susceptibility to conventional antibiotics.

•    New tools/assays: strategies and/or innovative tools or assays for the improvement or enhancement of the identification or validation of new effective compounds or therapies. Strategies and/or innovative tools for the optimisation the use, dosage and delivery of new drugs. Exploration of bacterial genes of interest.



This is a joint transnational call: applicants must apply as part of a transnational consortium.
Researchers from Ireland can apply as coordinators or partners. If successful, researchers from Ireland will be funded by the Health Research Board up to the maximum amount for the call. Applicants applying for funding from Ireland must be based at an eligible HRB Host Institution.
The following conditions apply to the composition of consortia:
•    Minimum of 3 partners from 3 different participating countries. These 3 partners should be eligible for funding by organisation listed in the table below.
•    No more than 2 partners can originate from the same country.
•    Maximum of 6 partners (excluding non-funded external collaborators participating with their own funding).

Individual country partners/coordinators should confirm eligibility with their national funding organisation contact point.   Further country specific guidance can be found on the call webpage



Proposals must be submitted to the Joint Call Secretariat (JCS) by the coordinator through the JPIAMR electronic submitting system exclusively ( .   Further details can be found in the call text. The call is a two-step application, with a first stage (pre-proposal submission) deadline of March 7th 2018. Invitations to submit full proposals will be issued in May 2018 with a full proposal submission deadline of 14th June 2018.



Amie Regan
01 2345178

Opening date
10:00 11-01-2018
Closing date
13:00 07-03-2018
Decision expected
Late 2018